When patients’ lives rely on a manufactured cell or gene therapy arriving exactly when and where it needs to, it is essential to ensure each step of the critical supply chain is managed as efficiently as possible. Cellular starting material collection is at the beginning of that supply chain, making cell collection processes vital to ensuring the quality and safety of these therapies. However, cell collection requirements for different treatments and companies vary and are often nuanced, raising the potential for error.

Learn more about how we are working to standardize common aspects of cell collection protocols and processes to increase the quality of cellular starting materials for emerging cell and gene therapies in our case study developed in partnership with the Standards Coordinating Body.